Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Germany equities were higher at the close on Thursday, as gains in the Technology, Telecoms and Media sectors propelled ...

added 4.64% or 1.37 points to end at 30.76 and Deutsche Telekom AG Na (ETR:DTEGn) was up 3.30% or 0.92 points to 28.77 in ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

The annual inflation rate in Sweden stood at 1.6% in October. On the corporate front, major European companies, including ...

European markets are heading for a mixed open Thursday as traders assessed the global inflation outlook and the possible ...

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...